Literature DB >> 15961548

Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids.

Christina V Obiezu1, Shannon J C Shan, Antoninus Soosaipillai, Liu-Ying Luo, Linda Grass, Georgia Sotiropoulou, Constantina D Petraki, Panos A Papanastasiou, Michael A Levesque, Eleftherios P Diamandis.   

Abstract

BACKGROUND: Human kallikrein 4 (hK4) is a proteolytic enzyme belonging to the tissue kallikrein family of serine proteases. Previous tissue expression studies have demonstrated highest KLK4 mRNA expression in prostatic tissue, but there has been only limited evidence for the presence of hK4 protein in prostate and other tissues and in corresponding biological secretions.
METHODS: To investigate the concentrations of hK4 in tissues and biological fluids, we developed a new hK4-specific sandwich-type immunoassay using a monoclonal antibody as the capture reagent.
RESULTS: The assay has a detection limit of 0.02 microg/L and <0.1% cross-reactivity toward any of the other 14 human kallikreins. Twelve of 40 tissue extracts prepared from various human tissues contained detectable hK4 concentrations (0.68-7143 ng/g of total protein), with healthy prostate tissue containing the highest amount of hK4. Examination of 16 malignant and 18 benign prostate tissues revealed no significant differences in hK4 protein content, and the tissues contained a wide range of values (benign, <0.02 to 801 ng/g; malignant, <0.02 to 824 ng/g). Among the biological fluids tested, seminal plasma and urine contained widely varying amounts of hK4; concentrations in 54 urine samples were <0.02 to 2.6 microg/L, whereas concentrations in 58 seminal plasma samples were 0.2-202 microg/L. Affinity purification of hK4 from seminal plasma and subsequent mass spectrometry demonstrated the secreted nature of hK4 in seminal plasma.
CONCLUSIONS: hK4 is found primarily in prostate tissue and is secreted in seminal plasma. Its value as a novel prostatic biomarker needs to be defined further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961548     DOI: 10.1373/clinchem.2005.049692

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  17 in total

1.  Expression of kallikrein-related peptidase 4 in dental and non-dental tissues.

Authors:  James P Simmer; Amelia S Richardson; Charles E Smith; Yuanyuan Hu; Jan C-C Hu
Journal:  Eur J Oral Sci       Date:  2011-12       Impact factor: 2.612

2.  Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.

Authors:  Yang Jin; Su Qu; Martina Tesikova; Ling Wang; Alexandr Kristian; Gunhild M Mælandsmo; Haiying Kong; Tianzhou Zhang; Carmen Jerónimo; Manuel R Teixeira; Erkan Yuca; Ibrahim Tekedereli; Kivanc Gorgulu; Neslihan Alpay; Anil K Sood; Gabriel Lopez-Berestein; Håvard E Danielsen; Bulent Ozpolat; Fahri Saatcioglu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

3.  Clinical significance of kallikrein-related peptidase-4 in oral cancer.

Authors:  Petros Papagerakis; Giuseppe Pannone; L I Zheng; Maria Athanassiou-Papaefthymiou; Yashuo Yamakoshi; Howard Stan McGuff; Omar Shkeir; Konstantinos Ghirtis; Silvana Papagerakis
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

4.  Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.

Authors:  Valérie Gratio; Nathalie Beaufort; Lina Seiz; Josefine Maier; G Duke Virca; Mekdes Debela; Nicolai Grebenchtchikov; Viktor Magdolen; Dalila Darmoul
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

5.  Discovery and validation of urinary biomarkers for prostate cancer.

Authors:  Dan Theodorescu; Eric Schiffer; Hartwig W Bauer; Friedrich Douwes; Frank Eichhorn; Reinhard Polley; Thomas Schmidt; Wolfgang Schöfer; Petra Zürbig; David M Good; Joshua J Coon; Harald Mischak
Journal:  Proteomics Clin Appl       Date:  2008-03-07       Impact factor: 3.494

Review 6.  Biomarkers for prostate cancer.

Authors:  Eric Schiffer
Journal:  World J Urol       Date:  2007-08-10       Impact factor: 4.226

7.  Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays.

Authors:  Theano D Karakosta; Antoninus Soosaipillai; Eleftherios P Diamandis; Ihor Batruch; Andrei P Drabovich
Journal:  Mol Cell Proteomics       Date:  2016-07-01       Impact factor: 5.911

8.  Enamel defects and ameloblast-specific expression in Enam knock-out/lacz knock-in mice.

Authors:  Jan C-C Hu; Yuanyuan Hu; Charles E Smith; Marc D McKee; J Timothy Wright; Yasuo Yamakoshi; Petros Papagerakis; Graeme K Hunter; Jerry Q Feng; Fumiko Yamakoshi; James P Simmer
Journal:  J Biol Chem       Date:  2008-02-04       Impact factor: 5.157

9.  Genetic association of the KLK4 locus with risk of prostate cancer.

Authors:  Felicity Lose; Srilakshmi Srinivasan; Tracy O'Mara; Louise Marquart; Suzanne Chambers; Robert A Gardiner; Joanne F Aitken; Amanda B Spurdle; Jyotsna Batra; Judith A Clements
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

10.  The solution structure of the kallikrein-related peptidases inhibitor SPINK6.

Authors:  Sascha Jung; Jan Fischer; Björn Spudy; Tim Kerkow; Frank D Sönnichsen; Li Xue; Alexandre M J J Bonvin; Peter Goettig; Viktor Magdolen; Ulf Meyer-Hoffert; Joachim Grötzinger
Journal:  Biochem Biophys Res Commun       Date:  2016-01-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.